RU2005141060A - Метаболит кветиапина - Google Patents

Метаболит кветиапина Download PDF

Info

Publication number
RU2005141060A
RU2005141060A RU2005141060/15A RU2005141060A RU2005141060A RU 2005141060 A RU2005141060 A RU 2005141060A RU 2005141060/15 A RU2005141060/15 A RU 2005141060/15A RU 2005141060 A RU2005141060 A RU 2005141060A RU 2005141060 A RU2005141060 A RU 2005141060A
Authority
RU
Russia
Prior art keywords
symptom
condition
yldibenzo
thiazepine
piperazin
Prior art date
Application number
RU2005141060/15A
Other languages
English (en)
Russian (ru)
Inventor
Скотт У. ГРИММ (US)
Скотт У. ГРИММ
Хелен Р. УИНТЕР (US)
Хелен Р. УИНТЕР
Патриси К. ДЕЙВИС (US)
Патрисия К. ДЕЙВИС
Реймонд Ф. СУКОУ (US)
Реймонд Ф. СУКОУ
Джеффри ГОЛДСТЕЙН (US)
Джеффри ГОЛДСТЕЙН
Original Assignee
Астразенека Аб (Se)
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб (Se), Астразенека Аб filed Critical Астразенека Аб (Se)
Publication of RU2005141060A publication Critical patent/RU2005141060A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2005141060/15A 2003-07-02 2004-06-28 Метаболит кветиапина RU2005141060A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48436503P 2003-07-02 2003-07-02
US60/484,365 2003-07-02

Publications (1)

Publication Number Publication Date
RU2005141060A true RU2005141060A (ru) 2006-07-27

Family

ID=33563981

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005141060/15A RU2005141060A (ru) 2003-07-02 2004-06-28 Метаболит кветиапина

Country Status (20)

Country Link
US (1) US20050026900A1 (enExample)
EP (1) EP1644005B1 (enExample)
JP (1) JP2007516193A (enExample)
KR (1) KR20060082037A (enExample)
CN (1) CN1816339B (enExample)
AR (1) AR045004A1 (enExample)
AT (1) ATE477803T1 (enExample)
AU (1) AU2004253334A1 (enExample)
BR (1) BRPI0412127A (enExample)
CA (1) CA2531284A1 (enExample)
DE (1) DE602004028739D1 (enExample)
ES (1) ES2349091T3 (enExample)
IL (1) IL172616A0 (enExample)
IS (1) IS8283A (enExample)
MX (1) MXPA05013869A (enExample)
NO (1) NO20060556L (enExample)
RU (1) RU2005141060A (enExample)
TW (1) TW200509944A (enExample)
UY (1) UY28400A1 (enExample)
WO (1) WO2005002586A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4414237B2 (ja) * 2002-03-20 2010-02-10 テバ ファーマシューティカル インダストリーズ リミティド ケチアピンヘミフマレートの結晶形
BRPI0417749A (pt) 2003-12-22 2007-04-10 Acadia Pharm Inc composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas
WO2008021463A2 (en) * 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
EP1838325A1 (en) * 2005-01-07 2007-10-03 AstraZeneca AB NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
US20060252744A1 (en) * 2005-04-04 2006-11-09 Burstein Ethan S Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents
JP2008502707A (ja) * 2005-04-14 2008-01-31 テバ ファーマシューティカル インダストリーズ リミティド クエチアピンフマレートの調製方法
WO2007004234A1 (en) * 2005-07-04 2007-01-11 Usv Limited A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE
EP1951694A4 (en) * 2005-11-18 2010-09-22 Astrazeneca Ab FORMS OF SALTS
US8389510B2 (en) 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
WO2007062338A2 (en) * 2005-11-18 2007-05-31 Astrazeneca Ab Solid formulations
JP2009516708A (ja) * 2005-11-18 2009-04-23 アストラゼネカ・アクチエボラーグ 液体製剤
EP1951257A4 (en) * 2005-11-18 2008-11-05 Astrazeneca Ab CRYSTALLINE FORMS
WO2008118141A2 (en) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
JP2010514682A (ja) * 2006-12-20 2010-05-06 アストラゼネカ・アクチエボラーグ 化合物及びその使用
JP2010514684A (ja) * 2006-12-20 2010-05-06 アストラゼネカ・アクチエボラーグ 化合物及びその使用
CN101616661A (zh) * 2006-12-20 2009-12-30 阿斯利康(瑞典)有限公司 化合物及其用途
CN101641101A (zh) * 2007-03-22 2010-02-03 阿斯利康(瑞典)有限公司 治疗心境障碍的方法
CN107714703A (zh) 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
RS58335B1 (sr) 2010-03-11 2019-03-29 Kempharm Inc Konjugati kvetiapina sa masnom kiselinom, proces za njihovo dobijanje i njihova primena
CN102552128B (zh) * 2012-02-28 2013-09-18 陆荣政 一种富马酸喹硫平注射液及其制备方法
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
GB1192812A (en) * 1966-05-20 1970-05-20 American Cyanamid Co 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3966949A (en) * 1973-10-12 1976-06-29 Richardson-Merrell Inc. Pharmaceutical compositions and preparing same
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5750566A (en) * 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
US6342488B1 (en) * 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
WO2004064753A2 (en) * 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc Use of n-desmethylclozapine to treat human neuropsychiatric disease

Also Published As

Publication number Publication date
ATE477803T1 (de) 2010-09-15
US20050026900A1 (en) 2005-02-03
WO2005002586A1 (en) 2005-01-13
IS8283A (is) 2006-02-01
CN1816339B (zh) 2010-12-15
UY28400A1 (es) 2005-01-31
KR20060082037A (ko) 2006-07-14
EP1644005B1 (en) 2010-08-18
EP1644005A1 (en) 2006-04-12
ES2349091T3 (es) 2010-12-27
AR045004A1 (es) 2005-10-12
JP2007516193A (ja) 2007-06-21
NO20060556L (no) 2006-04-03
CN1816339A (zh) 2006-08-09
TW200509944A (en) 2005-03-16
AU2004253334A1 (en) 2005-01-13
MXPA05013869A (es) 2006-02-28
DE602004028739D1 (de) 2010-09-30
CA2531284A1 (en) 2005-01-13
WO2005002586A8 (en) 2006-02-09
IL172616A0 (en) 2006-04-10
BRPI0412127A (pt) 2006-08-15

Similar Documents

Publication Publication Date Title
JP2007516193A5 (enExample)
MXPA05013869A (es) Metabolito de quetiapina.
GEP20125405B (en) Amino-heterocyclic compounds
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
HRP20110570T1 (hr) Amidi diazabicikloalkana selektivni na podvrstu nikotinskih acetilkolinskih receptora
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
GEP20104959B (en) Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
ATE454378T1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
BR0203274A (pt) teres aromáticos de difluorometilenos
MX2011011489A (es) Derivados de isoxazol-piridina.
SE0104341D0 (sv) New use
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
MX2011011273A (es) Derivados de isoxazol-pirazol.
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
NO20072046L (no) Halogensubstituerte benzodiazepinderivater
MXPA05013628A (es) Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3.
JP2007509960A5 (enExample)
ATE439363T1 (de) Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides
EE200100553A (et) Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
ATE402707T1 (de) Imidazoä1,5aütriazoloä1,5dübenzodiazepin- derivative zur behandlung kognitiver störungen
RU2003127718A (ru) Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости
MX2007007472A (es) Derivados de triazolona, tetrazolona e imidazolona para uso como antagonista del adrenorreceptor alfa-2c.
RU2008110945A (ru) N-оксиды как пролекарства производных пиперазина и пиперидина

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20070712

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20070726

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090303

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090303